Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children

Detalhes bibliográficos
Autor(a) principal: Fernandes, Eder Gatti
Data de Publicação: 2021
Outros Autores: López-Lopes, Giselle Ibette Silva, Silva, Valeria Oliveira, Yamashiro, Rosemeire, Madureira, Karen Cristina Rolim, Gallo, Juliana Failde, Lindoso, José Angelo, Sato, Helena Keico, Araujo, Núbia Virginia D’Avila Limeira de, Nerger, Maria Ligia Bacciotte Ramos, Brigido, Luis Fernando Macedo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista do Instituto de Medicina Tropical de São Paulo
Texto Completo: https://www.revistas.usp.br/rimtsp/article/view/193275
Resumo: Twenty-seven children aged seven months to 5 years were inadvertently vaccinated with a COVID-19 vaccine, the CoronaVac (Sinovac, China), an inactivated SARS-CoV-2 vaccine, in two different cities of Sao Paulo State, Brazil. After the event, these children were monitored by local pediatricians and serum samples were collected at the first visit and 30 days after vaccination and tested for SARS-CoV-2 S1 serology with Ortho total IgG anti-S1 protein and Cpass, an ACE2 receptor binding domain inhibition assay. Only one child had a mild symptom after vaccination, with no other adverse events documented up to the 30 days follow-up. Of 27 children tested 3-9 days after vaccination, 5 (19%) had positive serology suggesting a previous natural SARS-CoV-2 infection, with all 19 tested on day 30 after vaccination and presenting with positive tests, with an increment of antibody titers in those initially positive. A low Cpass binding inhibition was observed in the first collection in 11 seronegative cases, with high titers among those anti-S1 positive. All children showed an important increase in antibody titers on day 30. The event allowed the documentation of a robust serological response to one dose of CoronaVac in this small population of young children, with no major adverse effects. Although it was an unfortunate accident, this event may contribute with future vaccine strategies in this age group. The data suggest that CoronaVac is safe and immunogenic for children.
id IMT-1_c6788e30b47f25c9d83f52d52dc3301e
oai_identifier_str oai:revistas.usp.br:article/193275
network_acronym_str IMT-1
network_name_str Revista do Instituto de Medicina Tropical de São Paulo
repository_id_str
spelling Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy childrenCOVID-19 vaccinesAdverse eventsBrazilTwenty-seven children aged seven months to 5 years were inadvertently vaccinated with a COVID-19 vaccine, the CoronaVac (Sinovac, China), an inactivated SARS-CoV-2 vaccine, in two different cities of Sao Paulo State, Brazil. After the event, these children were monitored by local pediatricians and serum samples were collected at the first visit and 30 days after vaccination and tested for SARS-CoV-2 S1 serology with Ortho total IgG anti-S1 protein and Cpass, an ACE2 receptor binding domain inhibition assay. Only one child had a mild symptom after vaccination, with no other adverse events documented up to the 30 days follow-up. Of 27 children tested 3-9 days after vaccination, 5 (19%) had positive serology suggesting a previous natural SARS-CoV-2 infection, with all 19 tested on day 30 after vaccination and presenting with positive tests, with an increment of antibody titers in those initially positive. A low Cpass binding inhibition was observed in the first collection in 11 seronegative cases, with high titers among those anti-S1 positive. All children showed an important increase in antibody titers on day 30. The event allowed the documentation of a robust serological response to one dose of CoronaVac in this small population of young children, with no major adverse effects. Although it was an unfortunate accident, this event may contribute with future vaccine strategies in this age group. The data suggest that CoronaVac is safe and immunogenic for children.Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo2021-12-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/rimtsp/article/view/19327510.1590/S1678-9946202163083Revista do Instituto de Medicina Tropical de São Paulo; Vol. 63 (2021); e83Revista do Instituto de Medicina Tropical de São Paulo; Vol. 63 (2021); e83Revista do Instituto de Medicina Tropical de São Paulo; v. 63 (2021); e831678-99460036-4665reponame:Revista do Instituto de Medicina Tropical de São Pauloinstname:Instituto de Medicina Tropical (IMT)instacron:IMTenghttps://www.revistas.usp.br/rimtsp/article/view/193275/178134Copyright (c) 2021 Eder Gatti Fernandes, Giselle Ibette Silva López-Lopes, Valeria Oliveira Silva, Rosemeire Yamashiro, Karen Cristina Rolim Madureira, Juliana Failde Gallo, José Angelo Lindoso, Helena Keico Sato, Núbia Virginia D’Avila Limeira de Araujo, Maria Ligia Bacciotte Ramos Nerger, Luis Fernando Macedo Brigidohttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessFernandes, Eder Gatti López-Lopes, Giselle Ibette Silva Silva, Valeria Oliveira Yamashiro, Rosemeire Madureira, Karen Cristina Rolim Gallo, Juliana FaildeLindoso, José Angelo Sato, Helena Keico Araujo, Núbia Virginia D’Avila Limeira de Nerger, Maria Ligia Bacciotte Ramos Brigido, Luis Fernando Macedo 2022-05-16T13:44:35Zoai:revistas.usp.br:article/193275Revistahttp://www.revistas.usp.br/rimtsp/indexPUBhttps://www.revistas.usp.br/rimtsp/oai||revimtsp@usp.br1678-99460036-4665opendoar:2022-12-13T16:53:00.536530Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)true
dc.title.none.fl_str_mv Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
title Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
spellingShingle Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
Fernandes, Eder Gatti
COVID-19 vaccines
Adverse events
Brazil
title_short Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
title_full Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
title_fullStr Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
title_full_unstemmed Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
title_sort Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
author Fernandes, Eder Gatti
author_facet Fernandes, Eder Gatti
López-Lopes, Giselle Ibette Silva
Silva, Valeria Oliveira
Yamashiro, Rosemeire
Madureira, Karen Cristina Rolim
Gallo, Juliana Failde
Lindoso, José Angelo
Sato, Helena Keico
Araujo, Núbia Virginia D’Avila Limeira de
Nerger, Maria Ligia Bacciotte Ramos
Brigido, Luis Fernando Macedo
author_role author
author2 López-Lopes, Giselle Ibette Silva
Silva, Valeria Oliveira
Yamashiro, Rosemeire
Madureira, Karen Cristina Rolim
Gallo, Juliana Failde
Lindoso, José Angelo
Sato, Helena Keico
Araujo, Núbia Virginia D’Avila Limeira de
Nerger, Maria Ligia Bacciotte Ramos
Brigido, Luis Fernando Macedo
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Fernandes, Eder Gatti
López-Lopes, Giselle Ibette Silva
Silva, Valeria Oliveira
Yamashiro, Rosemeire
Madureira, Karen Cristina Rolim
Gallo, Juliana Failde
Lindoso, José Angelo
Sato, Helena Keico
Araujo, Núbia Virginia D’Avila Limeira de
Nerger, Maria Ligia Bacciotte Ramos
Brigido, Luis Fernando Macedo
dc.subject.por.fl_str_mv COVID-19 vaccines
Adverse events
Brazil
topic COVID-19 vaccines
Adverse events
Brazil
description Twenty-seven children aged seven months to 5 years were inadvertently vaccinated with a COVID-19 vaccine, the CoronaVac (Sinovac, China), an inactivated SARS-CoV-2 vaccine, in two different cities of Sao Paulo State, Brazil. After the event, these children were monitored by local pediatricians and serum samples were collected at the first visit and 30 days after vaccination and tested for SARS-CoV-2 S1 serology with Ortho total IgG anti-S1 protein and Cpass, an ACE2 receptor binding domain inhibition assay. Only one child had a mild symptom after vaccination, with no other adverse events documented up to the 30 days follow-up. Of 27 children tested 3-9 days after vaccination, 5 (19%) had positive serology suggesting a previous natural SARS-CoV-2 infection, with all 19 tested on day 30 after vaccination and presenting with positive tests, with an increment of antibody titers in those initially positive. A low Cpass binding inhibition was observed in the first collection in 11 seronegative cases, with high titers among those anti-S1 positive. All children showed an important increase in antibody titers on day 30. The event allowed the documentation of a robust serological response to one dose of CoronaVac in this small population of young children, with no major adverse effects. Although it was an unfortunate accident, this event may contribute with future vaccine strategies in this age group. The data suggest that CoronaVac is safe and immunogenic for children.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-09
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rimtsp/article/view/193275
10.1590/S1678-9946202163083
url https://www.revistas.usp.br/rimtsp/article/view/193275
identifier_str_mv 10.1590/S1678-9946202163083
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rimtsp/article/view/193275/178134
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo
publisher.none.fl_str_mv Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo
dc.source.none.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo; Vol. 63 (2021); e83
Revista do Instituto de Medicina Tropical de São Paulo; Vol. 63 (2021); e83
Revista do Instituto de Medicina Tropical de São Paulo; v. 63 (2021); e83
1678-9946
0036-4665
reponame:Revista do Instituto de Medicina Tropical de São Paulo
instname:Instituto de Medicina Tropical (IMT)
instacron:IMT
instname_str Instituto de Medicina Tropical (IMT)
instacron_str IMT
institution IMT
reponame_str Revista do Instituto de Medicina Tropical de São Paulo
collection Revista do Instituto de Medicina Tropical de São Paulo
repository.name.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)
repository.mail.fl_str_mv ||revimtsp@usp.br
_version_ 1798951653747982336